These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1181 related items for PubMed ID: 22941374

  • 1. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S, Zhang XC, Cheng H, Zhu JQ, Chen ZH, Zhang YF, Xie Z, Wu YL.
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [Abstract] [Full Text] [Related]

  • 2. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A.
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [Abstract] [Full Text] [Related]

  • 3. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
    Huang Y, Chen Y, Mei Q, Chen Y, Yu S, Xia S.
    Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
    [Abstract] [Full Text] [Related]

  • 4. Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines.
    La Monica S, Galetti M, Alfieri RR, Cavazzoni A, Ardizzoni A, Tiseo M, Capelletti M, Goldoni M, Tagliaferri S, Mutti A, Fumarola C, Bonelli M, Generali D, Petronini PG.
    Biochem Pharmacol; 2009 Sep 01; 78(5):460-8. PubMed ID: 19427302
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7117-25. PubMed ID: 17145836
    [Abstract] [Full Text] [Related]

  • 6. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M, Yuan Y, Pan YY, Zhang Y.
    Mol Med Rep; 2014 Jun 01; 9(6):2417-22. PubMed ID: 24682085
    [Abstract] [Full Text] [Related]

  • 7. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Wu M, Yuan Y, Pan YY, Zhang Y.
    Mol Med Rep; 2014 Aug 01; 10(2):931-8. PubMed ID: 24840891
    [Abstract] [Full Text] [Related]

  • 8. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects.
    Shen H, Yuan Y, Sun J, Gao W, Shu YQ.
    Biomed Pharmacother; 2010 Feb 01; 64(2):88-92. PubMed ID: 20005069
    [Abstract] [Full Text] [Related]

  • 9. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
    Morgillo F, Sasso FC, Della Corte CM, Vitagliano D, D'Aiuto E, Troiani T, Martinelli E, De Vita F, Orditura M, De Palma R, Ciardiello F.
    Clin Cancer Res; 2013 Jul 01; 19(13):3508-19. PubMed ID: 23695170
    [Abstract] [Full Text] [Related]

  • 10. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
    Clin Cancer Res; 2009 Feb 01; 15(3):907-13. PubMed ID: 19188161
    [Abstract] [Full Text] [Related]

  • 11. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
    Choi YJ, Rho JK, Jeon BS, Choi SJ, Park SC, Lee SS, Kim HR, Kim CH, Lee JC.
    Cancer Chemother Pharmacol; 2010 Jul 01; 66(2):381-8. PubMed ID: 19921194
    [Abstract] [Full Text] [Related]

  • 12. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F, Zhu T, Cao B, Wang J, Liang L.
    Eur J Cancer; 2017 Oct 01; 84():184-192. PubMed ID: 28822888
    [Abstract] [Full Text] [Related]

  • 13. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M, He CS, Wei SH, Zhang L.
    Eur J Cancer; 2013 Nov 01; 49(16):3559-72. PubMed ID: 23916913
    [Abstract] [Full Text] [Related]

  • 14. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
    Jiang Y, Li C, Ma Y, Chen J, Li Y, Chen L.
    Clin Lab; 2012 Nov 01; 58(5-6):551-61. PubMed ID: 22783588
    [Abstract] [Full Text] [Related]

  • 15. Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib.
    Xu R, Shen H, Guo R, Sun J, Gao W, Shu Y.
    Biomed Pharmacother; 2012 Jul 01; 66(5):384-9. PubMed ID: 22560634
    [Abstract] [Full Text] [Related]

  • 16. In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.
    Cheng H, An SJ, Zhang XC, Dong S, Zhang YF, Chen ZH, Chen HJ, Guo AL, Lin QX, Wu YL.
    Cancer Chemother Pharmacol; 2011 Mar 01; 67(3):637-46. PubMed ID: 20495920
    [Abstract] [Full Text] [Related]

  • 17. Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
    Tsai CM, Chen JT, Chiu CH, Lai CL, Hsiao SY, Chang KT.
    Lung Cancer; 2013 Nov 01; 82(2):305-12. PubMed ID: 24055492
    [Abstract] [Full Text] [Related]

  • 18. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.
    Cancer Res; 2004 Aug 01; 64(15):5355-62. PubMed ID: 15289342
    [Abstract] [Full Text] [Related]

  • 19. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.
    Int J Oncol; 2013 Jun 01; 42(6):2094-102. PubMed ID: 23588221
    [Abstract] [Full Text] [Related]

  • 20. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY, Zhao MB, Zhuang GB, Li PP.
    Lung Cancer; 2012 Jan 01; 75(1):30-7. PubMed ID: 21757251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.